Analysts’ Top Healthcare Picks: MEIP, RXII

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MEI Pharma (NASDAQ: MEIP) and RXi Pharmaceuticals Corp (NASDAQ: RXII) with bullish sentiments.

MEI Pharma (MEIP)

In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on MEI Pharma, with a price target of $6. The company’s shares closed on Friday at $4.41.

Cann observed:

“We rate MEI Pharma, a development-stage biotechnology company working in epigenetics, the PI3K pathway and cancer metabolism, Outperform. We are increasing our price target to account for an increased average forward price-to-sales multiple of the biotechnology sector.”

According to, Cann is a 5-star analyst with an average return of 26.5% and a 61.3% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.

Currently, the analyst consensus on MEI Pharma is a Moderate Buy with an average price target of $6.

See today’s analyst top recommended stocks >>

RXi Pharmaceuticals Corp (RXII)

H.C. Wainwright analyst Ram Selvaraju initiated coverage with a Buy rating on RXi Pharmaceuticals Corp today and set a price target of $3. The company’s shares closed on Friday at $1.97, close to its 52-week low of $1.78.

Selvaraju wrote:

“We are initiating coverage of RXi Pharmaceuticals, an emerging biotechnology company dedicated to improving the efficiency and anti- tumor activity of cell-based immunotherapy (principally via adoptive cell transfer) using RNA interference (RNAi). RXi possesses a proprietary technology platform of self-delivering RNAi (sd-rxRNA), which has demonstrated clinical safety in various topical formulations. The company is using this technology in an ex vivo setting so as to enhance the activity of immune cells being used to treat cancer. Cell-based immunotherapy is one of the core pillars of the so-called immuno- oncology (I/O) field, which co-opts the immune system to fight the patient’s cancer by arming and activating immune cells to infiltrate tumors and kill cancer cells. Our rating is 12-month price target of $3.00 per share.”

According to, Selvaraju is a 2-star analyst with an average return of 0.5% and a 43.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

RXi Pharmaceuticals Corp has an analyst consensus of Moderate Buy, with a price target consensus of $3.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.